News ImmuneRegen NewsThursday November 6, 6:30 am ET ImmuneRegen BioSciences to Present at Rodman & Renshaw 10th Annual Global Healthcare ConferenceCEO to Address Top Biotechnology and Life Sciences Investors About Drug-Candidate, Homspera SCOTTSDALE, AZ--(MARKET WIRE)--Nov 6, 2008 -- ImmuneRegen BioSciences, Inc., a development-stage biotechnology company and wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC BB:IRBS.OB - News), will present at the Rodman & Renshaw 10th Annual Global Healthcare Conference, Nov. 10 - 12, in New York City. Michael Wilhelm, president and CEO of ImmuneRegen, and the Company's key science directors will speak on Nov. 10th at 12:25 p.m. ESTand will then be available to meet with potential investors and industry analysts. The presentation will focus on the investment opportunity surrounding the Company's compound, Homspera®, an adult stem cell active peptide that has been shown in preclinical studies to regenerate and strengthen the immune system, as well as enhance wound healing. Wilhelm and his team will also provide an update on the Company's product pipeline and showcase its partnerships with industry and academic leaders. According to Wilhelm, "Ongoing positive study findings about Homspera's role in enhancing adult stem cell activity in bone marrow have generated increasing interest in licensing and/or collaborative opportunities related to this innovative compound. This conference provides an excellent opportunity to share current findings pertaining to Homspera's potential applications." ImmuneRegen's focus is to collaborate and/or license Homspera for further therapeutic development. Homspera's preclinical effectiveness has been evident as protection from radiation exposure, acceleration of wound healing, vaccine adjuvancy, and treatment of infectious diseases, such as influenza and anthrax. Underlying these results is the ability of Homspera to stimulate stem cells that regenerate and maintain the immune system. For example, the survival increases observed in the Company's radiation studies suggests Homspera mitigates the resulting neutropenia and thrombocytopenia, thereby restoring the damaged immune system. The Conference will feature corporate presentations by innovative biotechnology and life sciences companies to an expected 3,500 attendees (40% more than last year) including institutional investors, venture capitalists, sophisticated private investors as well as business development and partnering executives and experts from the global medical and research communities. The presentations are by invitation only. About Rodman & RenshawRodman & Renshaw Capital Group, Inc., through its subsidiaries, engages in investment banking business. It offers corporate finance services focusing on various public and private equity products, which include private investment in public equity, registered direct offerings, private placements, and public offerings, as well as provides Collateralized Acquisition Pool, a product used to facilitate a targeted acquisition. The company also provides strategic advisory services, which include identifying and evaluating acquisition targets or acquirers; providing valuation analyses; evaluating and proposing financial and strategic alternatives; rendering fairness opinions; advising on timing, structure, and pricing of transaction; assisting in negotiating and closing a transaction; advising on the sale process; and assisting in preparing a memorandum or other sales materials. In addition, it provides merchant banking and asset management services. The company is headquartered in New York, New York. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|